Every 424B that First Tracks Biotherapeutics, Inc. (TRAX) has filed with the SEC in the last 12 months is listed below, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A 424B covers the supplement that carries the terms of a priced offering, so if you follow TRAX and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full TRAX filings page.
First Tracks Biotherapeutics, Inc., a clinical-stage biotechnology company focused on autoimmune and inflammatory diseases, has registered for resale by selling stockholders up to 10,497,054 shares of common stock; the company will not receive any proceeds from these sales. The business was separated from AnaptysBio via a Spin-Off completed on April 20, 2026, and concurrently raised approximately $80 million gross in a private placement of 5,791,479 primary shares at $13.81 per share.
As of June 30, 2026, cash and cash equivalents were $168.0 million and total assets were $183.1 million, with 35,390,679 shares of common stock outstanding. For the six months ended June 30, 2026, the company reported a net loss of $83.9 million, driven by research and development expenses of $59.6 million and general and administrative expenses of $28.1 million, partially offset by $3.9 million of interest income. Management states existing resources are expected to fund operating plans for at least 12 months. The pipeline includes ANB033 for celiac disease and eosinophilic esophagitis, rosnilimab for rheumatoid arthritis, and ANB101, a BDCA2 modulator.
First Tracks Biotherapeutics supplements its prospectus to register the resale by selling stockholders of up to 10,497,054 shares of common stock. The Company states it will not receive any proceeds from the sale of these Resale Shares. The prospectus supplement incorporates the Company's Form 10-Q for the quarter ended March 31, 2026. Shares outstanding were 34,892,381 as of May 12, 2026.
First Tracks Biotherapeutics, Inc. registers 10,497,054 shares of common stock for resale by selling stockholders, with no proceeds payable to the company from the resale. The registration covers resale of shares issued in a March 26, 2026 private placement, which included 5,791,479 Primary Shares and 4,705,575 Secondary Shares. The Private Placement generated approximately $80 million of gross proceeds to the company from the Primary Shares. The prospectus states the selling stockholders may sell at prevailing market prices or in privately negotiated transactions; the prospectus date is May 14, 2026 and the Nasdaq closing price on May 13, 2026 was $18.43 per share.